# Active Symptom Control Alone Or In Combination With Oral Topotecan In Patients With Relapsed Resistant Small Cell Lung Cancer

> **NCT00276276** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 141 (—)

## Conditions studied

- Lung Cancer, Small Cell

## Interventions

- **DRUG:** topotecan

## Key facts

- **NCT ID:** NCT00276276
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-11
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 141 (—)
- **Last updated:** 2013-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00276276

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00276276, "Active Symptom Control Alone Or In Combination With Oral Topotecan In Patients With Relapsed Resistant Small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00276276. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*